Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$63K Buy
2,245
+2
+0.1% +$53 0.03% 172
2025
Q4
$55.8K Buy
2,243
+3
+0.1% +$76 0.03% 177
2025
Q3
$57.1K Buy
2,240
+3
+0.1% +$74 0.03% 169
2025
Q2
$54.2K Buy
2,237
+3
+0.1% +$70 0.03% 193
2025
Q1
$56.6K Sell
2,234
-2,488
-53% -$65.1K 0.04% 175
2024
Q4
$125K Buy
4,722
+1,768
+60% +$48K 0.04% 172
2024
Q3
$85.5K Buy
+2,954
New +$86.2K 0.05% 164

Other funds holding PFE

Hara Capital's PFE Position: Q1 2026 in Review

Hara Capital increased its Pfizer (PFE) stake by 0.09% in Q1 2026, buying an estimated $53 and bringing the position to 2,245 shares worth $63K. The position accounts for 0.03% of the portfolio, ranked #172.

Hara Capital first reported a position in PFE in Q3 2024 and has held it in 7 quarters since. The position peaked at $125K in Q4 2024. 2,938 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Hara Capital held 2,245 shares of Pfizer worth $63K as of Q1 2026.
  • Hara Capital bought 2 Pfizer shares in Q1 2026, an estimated $53.
  • Pfizer made up 0.03% of Hara Capital's portfolio in Q1 2026, its #172 holding.
  • Hara Capital first reported a position in Pfizer in Q3 2024 and has held it in 7 quarters since.
  • Hara Capital's Pfizer position peaked at $125K in Q4 2024.
  • 2,938 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Hara Capital's 13F filing for Q1 2026, filed 14 May 2026.